JP5893738B2 - グリコシダーゼ阻害剤としてのピラノ[3,2−d][1,3]チアゾール - Google Patents

グリコシダーゼ阻害剤としてのピラノ[3,2−d][1,3]チアゾール Download PDF

Info

Publication number
JP5893738B2
JP5893738B2 JP2014527246A JP2014527246A JP5893738B2 JP 5893738 B2 JP5893738 B2 JP 5893738B2 JP 2014527246 A JP2014527246 A JP 2014527246A JP 2014527246 A JP2014527246 A JP 2014527246A JP 5893738 B2 JP5893738 B2 JP 5893738B2
Authority
JP
Japan
Prior art keywords
compound
atoms
pyrano
disease
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014527246A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014527060A5 (enExample
JP2014527060A (ja
Inventor
ドネリー,マリアンヌ
チウ,ホゥイ
ユウ,ヘンリー
リウ−ブジャルスキ,レスリー
ゴウトポウロス,アンドレアス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2014527060A publication Critical patent/JP2014527060A/ja
Publication of JP2014527060A5 publication Critical patent/JP2014527060A5/ja
Application granted granted Critical
Publication of JP5893738B2 publication Critical patent/JP5893738B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/056—Triazole or tetrazole radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/06—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2014527246A 2011-08-25 2012-08-22 グリコシダーゼ阻害剤としてのピラノ[3,2−d][1,3]チアゾール Active JP5893738B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161527323P 2011-08-25 2011-08-25
US61/527,323 2011-08-25
PCT/US2012/051785 WO2013028715A1 (en) 2011-08-25 2012-08-22 Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors

Publications (3)

Publication Number Publication Date
JP2014527060A JP2014527060A (ja) 2014-10-09
JP2014527060A5 JP2014527060A5 (enExample) 2015-10-29
JP5893738B2 true JP5893738B2 (ja) 2016-03-23

Family

ID=46759099

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014527246A Active JP5893738B2 (ja) 2011-08-25 2012-08-22 グリコシダーゼ阻害剤としてのピラノ[3,2−d][1,3]チアゾール

Country Status (21)

Country Link
US (2) US8884023B2 (enExample)
EP (1) EP2748171B1 (enExample)
JP (1) JP5893738B2 (enExample)
KR (1) KR102008032B1 (enExample)
CN (1) CN103930428B (enExample)
AU (1) AU2012298949B2 (enExample)
BR (1) BR112014004219B1 (enExample)
CA (1) CA2845149C (enExample)
DK (1) DK2748171T3 (enExample)
EA (1) EA022562B1 (enExample)
ES (1) ES2568603T3 (enExample)
HR (1) HRP20160334T1 (enExample)
HU (1) HUE029390T2 (enExample)
IL (1) IL231008A (enExample)
MX (1) MX358463B (enExample)
PL (1) PL2748171T3 (enExample)
RS (1) RS54773B1 (enExample)
SG (1) SG2014009617A (enExample)
SI (1) SI2748171T1 (enExample)
WO (1) WO2013028715A1 (enExample)
ZA (1) ZA201400387B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201249848A (en) 2010-11-08 2012-12-16 Merck Sharp & Dohme Selective glycosidase inhibitors and uses thereof
BR112013016179A2 (pt) 2010-12-23 2018-07-10 Alectos Therapeutics Inc inibidores seletivos da glicosidase e usos dos mesmos.
WO2012126091A1 (en) 2011-03-24 2012-09-27 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US9718854B2 (en) * 2011-03-31 2017-08-01 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2013000085A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
MX364602B (es) 2011-06-27 2019-05-02 Alectos Therapeutics Inc Inhibidores selectivos de glicosidasa y usos de los mismos.
WO2013000086A1 (en) 2011-06-27 2013-01-03 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
US8884023B2 (en) * 2011-08-25 2014-11-11 Merck Patent Gmbh Pyrano [3,2-D][1,3]thiazole as glycosidase inhibitors
EP2890675A4 (en) 2012-08-31 2016-01-13 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
EP2890676B1 (en) 2012-08-31 2018-12-05 Alectos Therapeutics Inc. Glycosidase inhibitors and uses thereof
EP2914604A4 (en) 2012-10-31 2016-07-20 Alectos Therapeutics Inc GLYCOSIDASE INHIBITORS AND USES THEREOF
WO2014100934A1 (en) * 2012-12-24 2014-07-03 Merck Sharp & Dohme Corp. Glycosidase inhibitors and uses thereof
MX381417B (es) 2014-08-28 2025-03-12 Asceneuron Sa Inhibidores de glucosidasa.
US10571963B2 (en) * 2015-09-18 2020-02-25 Toray Industries, Inc. Housing
JP6971999B2 (ja) 2016-02-25 2021-11-24 エースニューロン・ソシエテ・アノニム ピペラジン誘導体の酸付加塩
CN108884077A (zh) 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
JP2019506430A (ja) 2016-02-25 2019-03-07 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
WO2020039029A1 (en) 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
CA3110032A1 (en) 2018-08-22 2020-02-27 Asceneuron S.A. Succinate and fumarate acid addition salts of piperazine derivatives
TW202130643A (zh) * 2019-10-29 2021-08-16 美商百健Ma公司 螺環o-醣蛋白-2-乙醯胺基-2-去氧-3-d-葡萄哌喃糖苷酶抑制劑

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006220187B2 (en) * 2005-03-01 2012-11-08 Simon Fraser University Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof
AU2007210002A1 (en) * 2006-01-30 2007-08-09 Irm Llc Compounds and compositions as PPAR modulators
CN101595111A (zh) * 2006-08-31 2009-12-02 西蒙·弗雷瑟大学 选择性糖苷酶抑制剂及其用途
EP2057171A4 (en) * 2006-08-31 2010-04-21 Univ Fraser Simon SELECTIVE GLYCOSIDASE INHIBITORS AND APPLICATIONS THEREOF
US9120781B2 (en) 2010-05-11 2015-09-01 Simon Fraser University Selective glycosidase inhibitors and uses thereof
WO2012061972A1 (en) 2010-11-08 2012-05-18 Alectos Therapeutics Inc. Selective glycosidase inhibitors and uses thereof
WO2012061927A1 (en) 2010-11-08 2012-05-18 Alectos Therapeutics, Inc. Selective glycosidase inhibitors and uses thereof
BR112013016179A2 (pt) 2010-12-23 2018-07-10 Alectos Therapeutics Inc inibidores seletivos da glicosidase e usos dos mesmos.
US8884023B2 (en) * 2011-08-25 2014-11-11 Merck Patent Gmbh Pyrano [3,2-D][1,3]thiazole as glycosidase inhibitors

Also Published As

Publication number Publication date
SG2014009617A (en) 2014-05-29
CN103930428A (zh) 2014-07-16
US20150018318A1 (en) 2015-01-15
KR102008032B1 (ko) 2019-08-06
HK1196607A1 (zh) 2014-12-19
US20140243370A1 (en) 2014-08-28
IL231008A (en) 2016-04-21
BR112014004219B1 (pt) 2021-11-30
RS54773B1 (sr) 2016-10-31
ES2568603T3 (es) 2016-05-03
BR112014004219A2 (pt) 2017-03-14
EP2748171B1 (en) 2016-02-03
CA2845149A1 (en) 2013-02-28
DK2748171T3 (en) 2016-05-09
ZA201400387B (en) 2015-05-27
MX2014002031A (es) 2014-03-21
EA201490493A1 (ru) 2014-06-30
EA022562B1 (ru) 2016-01-29
IL231008A0 (en) 2014-03-31
CN103930428B (zh) 2016-05-11
EP2748171A1 (en) 2014-07-02
HUE029390T2 (en) 2017-02-28
AU2012298949B2 (en) 2016-09-22
WO2013028715A1 (en) 2013-02-28
AU2012298949A1 (en) 2014-01-30
SI2748171T1 (sl) 2016-06-30
US8884023B2 (en) 2014-11-11
KR20140054007A (ko) 2014-05-08
HRP20160334T1 (hr) 2016-05-06
CA2845149C (en) 2019-12-31
MX358463B (es) 2018-08-22
US9469657B2 (en) 2016-10-18
JP2014527060A (ja) 2014-10-09
PL2748171T3 (pl) 2016-06-30

Similar Documents

Publication Publication Date Title
JP2014527060A (ja) グリコシダーゼ阻害剤としてのピラノ[3,2−d][1,3]チアゾール
JP7082446B2 (ja) スルホキシイミングリコシダーゼ阻害剤
AU2015308437B2 (en) Glycosidase inhibitors
CA3053200C (en) Sulfoximine glycosidase inhibitors
WO2020039028A1 (en) Tetrahydro-benzoazepine glycosidase inhibitors
WO2020169804A1 (en) Fused glycosidase inhibitors
WO2019037860A1 (en) LINEAR INHIBITORS OF GLYCOSIDASE
WO2018153507A1 (en) Substituted dihydrobenzofuran glycosidase inhibitors
HK1196607B (en) Pyrano [3, 2 - d] [1, 3] thiazole as glycosidase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150826

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20150826

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20150916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160104

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160125

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160224

R150 Certificate of patent or registration of utility model

Ref document number: 5893738

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250